Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2007 1
2008 1
2009 2
2010 1
2013 1
2015 1
2016 2
2017 3
2018 3
2019 1
2020 3
2021 5
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Expanding the spectrum of inflammatory spinal disease: AS it was, as it is now.
Isdale A, Keat A, Barkham N, Bennett AN, Gaffney K, Marzo-Ortega H, Sengupta R. Isdale A, et al. Among authors: barkham n. Rheumatology (Oxford). 2013 Dec;52(12):2103-5. doi: 10.1093/rheumatology/ket244. Epub 2013 Jul 19. Rheumatology (Oxford). 2013. PMID: 23873819 No abstract available.
Are telephone consultations here to stay in rheumatology?
Raizada SR, Cleaton N, Bateman J, Mulherin DM, Barkham N. Raizada SR, et al. Among authors: barkham n. Rheumatol Adv Pract. 2020 Dec 16;5(1):rkaa071. doi: 10.1093/rap/rkaa071. eCollection 2021. Rheumatol Adv Pract. 2020. PMID: 33511325 Free PMC article.
Acute pseudogout - Measure serum magnesium.
Gama RM, Barkham N, Ward J, Gama R, Borovickova I. Gama RM, et al. Among authors: barkham n. Ann Clin Biochem. 2019 May;56(3):411-414. doi: 10.1177/0004563219826169. Epub 2019 Feb 27. Ann Clin Biochem. 2019. PMID: 30813745
Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC).
Ajibade A, Pandian H, Jain N, Gupta L, Laxminarayan R, Moorthy A, Amarasena R, Cox N, Sapkota H, Kakade G, Elamanchi S, Prabu A, Al-Samaraaie E, Barkham N. Ajibade A, et al. Among authors: barkham n. Rheumatol Adv Pract. 2023 Mar 8;7(1):rkad029. doi: 10.1093/rap/rkad029. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 36938322 Free PMC article. No abstract available.
The impact of the COVID-19 pandemic and stringent social distancing measures on health-related quality of life and COVID-19 infection rates in patients with rheumatic disease: a longitudinal analysis through the pandemic.
Cox N, Raizada SR, Barkham N, Venkatachalam S, Sheeran TP, Adizie T, Sapkota H, Scott IC, Muller S, Bateman J. Cox N, et al. Among authors: barkham n. Rheumatol Adv Pract. 2023 Jan 16;7(1):rkad009. doi: 10.1093/rap/rkad009. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 36751643 Free PMC article.
28 results